Related Experiment Video
Updated: Jun 19, 2026
06:00
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Pin1 as an anticancer drug target.
Guoyan G Xu1, Felicia A Etzkorn
1Virginia Tech, Department of Chemistry, Blacksburg, Virginia, USA.
Drug News & Perspectives
|November 6, 2009
Summary
Pin1 protein isomerase is overexpressed in human cancers and drives tumor growth. Inhibiting Pin1 may offer a novel therapeutic strategy for cancer treatment by inducing apoptosis and blocking cell cycle progression.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Pin1 (Peptidyl-prolyl cis-trans isomerase) catalyzes cis/trans isomerization of phospho-Ser/Thr-Pro bonds.
- This isomerization affects the function of key substrates like Cdc25C, c-Jun, and p53, influencing critical cellular events.
- Pin1 overexpression is observed in various human cancers, correlating with elevated cyclin D1 levels and contributing to cell transformation.
Purpose of the Study:
- To highlight the role of Pin1 in oncogenesis.
- To establish Pin1 as a potential anticancer therapeutic target.
- To review existing Pin1 inhibitors and their therapeutic potential.
Main Methods:
- Literature review of Pin1's enzymatic activity and biological roles.
- Analysis of Pin1 expression in human cancer tissues.
- Survey of identified Pin1 inhibitors, including designed and natural products.
Main Results:
- Pin1 overexpression promotes tumor growth and is linked to cyclin D1 levels.
- Inhibition of Pin1 induces tumor cell apoptosis and blocks cell cycle progression.
- Various classes of Pin1 inhibitors have been identified, including small molecules and natural products.
Conclusions:
- Pin1 is a critical factor in oncogenesis and a promising anticancer drug target.
- Pin1 inhibitors represent a novel therapeutic approach for cancer treatment.
- Pin1's role in cell cycle regulation makes it a valuable target for diagnostic and therapeutic strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...